With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.208167-83-3,tert-Butyl 4-(2-chloroethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
To a solution of 6-(tert-butylsulfonyl)-4-((5-fluoro-lH-indazol-3-yl)amino)quinolin-7-ol (100 mg, 0.24 mmol) and tert-butyl 4-(2-chloroethyl)piperazine-l-carboxylate (72 mg, 0.20 mmol) in N,N- Dimethylformamide (DMF) (0.8 mL) was added potassium carbonate (50.0 mg, 0.36 mmol) and sodium iodide (7.2 mg, 0.05 mmol). The reaction was warmed to 50 C and stirred under an atmosphere of nitrogen. It was cooled to room temperature and concentrated under vacuum. The residue was subjected directly to purification by flash chromatography (60g pre-packed C-18 SNAP cartridge: 40% to 90% acetonitrile (0.1% ammonia) in water (10 mM ammonium bicarbonate)). The desired fractions were combined and concentrated to afford the title compound (100 mg, 0.16 mmol, 66 % yield). LCMS Method B T= 1.18 min, ES+ve 627.
208167-83-3, As the paragraph descriping shows that 208167-83-3 is playing an increasingly important role.
Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; CASILLAS, Linda N.; HARLING, John David; MIAH, Afjal Hussain; SMITH, Ian Edward David; RACKHAM, Mark David; (204 pag.)WO2017/182418; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics